A Study to Evaluate Immune Features of Inflammatory Arthritis As It Correlates with Imbalance Between T-cell Exhaustion and Senescence


About this study

The purpose of this study is to systematically examine the immunological features between IA-irAE, classic inflammatory arthritis, ICI-controls and HC.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults, ≥ 18 years of age.
  • For rheumatoid arthritis patients:
    • 2010 EULAR/ACR classification criteria of RA.
  • For cancer patients on ICI therapy without irAEs, they will be matched to our existing IA-irAE patients by age, sex, cancer types and ICI treatment.

Exclusion Criteria:

  • < 18 years of age.
  • For rheumatoid arthritis cohort:
    • Active infection;
    • Pregnancy;
    • Any cancer diagnosis;
    • Treatment with biologics;
    • Active use of high dose (≥ 30 mg daily) of prednisone or steroid equivalent;
    • Clinical features suggestive of other non-RA rheumatic disease (e.g., psoriatic arthritis, reactive arthritis, ankylosing spondylitis, lupus, Sjogren’s, , etc) or axial spondyloarthropathy.
  • For cancer patient control cohort:
    • No irAE ≤ 6 months following final ICI treatment.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hu Zeng, Ph.D.

Open for enrollment

Contact information:

Kathleen McCarthy-Fruin

(507) 284-4797


More information


Publications are currently not available

Mayo Clinic Footer